Serum and follicular fluid thyroid hormone levels and assisted reproductive technology outcomes

Yun Ying Cai 1,2, Na Lin 3, Lan Ping Zhong 3, Hui Juan Duan 2, Yun Hua Dong 3, Ze Wu 3* and Heng Su 1,2*

Abstract

Objective: The objective of this study was to assess the association between thyroid hormone (TH) levels in follicular fluid (FF) and serum and to determine whether THs impact assisted reproductive technology (ART) outcomes.

Methods: This study enrolled 299 women undergoing ART. Blood samples were drawn on the day of human chorionic gonadotrophin (HCG) administration and analysed for thyroid-stimulating hormone (TSH), thyroxine (T4), triiodothyronine (T3), free T4 (fT4), free T3 (fT3), thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels. FF was obtained on the oocyte pick up (OPU) day and analysed for TSH, T4, T3, fT4, fT3, TPOAbs, TgAbs and estradiol levels.

Results: (1) There were significant positive correlations between serum and FF TH and thyroid autoantibody levels. Statistically significant differences were discovered in serum and FF levels of TSH ($p \leq 0.001$), T4 ($p \leq 0.001$), T3 ($p \leq 0.001$), TPOAbs ($p \leq 0.001$) and TgAbs ($p = 0.021$). (2) Serum T4 levels [121.9(104.8,140.8) vs 114.1(98.6,130.6) nmol/l, $p = 0.026$], serum fT4 levels [(19.0 (17.7, 21.8) vs 18.6 (17.0, 20.1) pmol/l, $p = 0.026$], serum T4/T3 ratios [62.5 (55.7, 66.2) vs 59.4 (53.4, 64.9), $p = 0.029$], FF fT4 levels [19.0 (17.5, 21.3) vs 18.1 (16.8, 19.9) pmol/l, $p = 0.009$] and FF T4/T3 ratios [52.6 (46.4, 57.3) vs 50.0 (43.7, 53.1), $p = 0.004$] were significantly higher in the successful pregnancy group than the implantation failure group. (3) Spearman’s rank correlation analysis revealed positive associations of both the FF T4/T3 ratio and serum TSH levels with the numbers of retrieved oocytes (total or MII) and embryos (fertilized, cleavage, and good quality).

Conclusions: TH levels in FF are strongly correlated with those in serum on the HCG day, and THs on the HCG day may affect ART outcomes.

Keywords: Thyroid hormones, Follicular fluid, Controlled ovarian hyperstimulation, Thyroid autoimmunity

Introduction

Thyroid hormones (THs) are related to infertility and multiple adverse neonatal and maternal consequences [1, 2]. Recently, many studies have evaluated the relationship between ART outcomes and thyroid function [3–5]. A growing body of literature debates what constitutes “normal” gestational and preconceptional thyroid function and treatment cut-offs [4, 5]. The latest meta-analysis on preconception subclinical hypothyroidism (SCH), which included 14,846 participants, found no significant differences in ART-related outcomes between different thyroid-stimulating hormone (TSH) level groups when the TSH cut-off was set to 2.5 mIU/L. However, when a broader TSH cut-off range (3.5–5 mIU/L) was used, the miscarriage rate was higher in the preconception SCH group than in the normal group [4]. On the other hand, several studies of euthyroid infertile women undergoing intrauterine insemination (IUI) [6–8], found no differences in TSH levels among different IUI outcome groups. In addition, most previous studies categorized women with no
history of thyroid disease and normal TSH levels as euthyroid; TH levels and thyroid antibody status were not known.

Follicular fluid (FF) supports the acquisition of development competence in oocytes [9, 10], and provides the important microenvironment for oocyte maturation. Changes in the FF levels of hormones and metabolites have been reported to influence oocyte quality, early embryo development, and subsequent pregnancy [11, 12]. Since biological effects of THs are regulated by deiodinase (DIO) in peripheral tissue [13, 14], serum TH levels do not always predict tissue-specific effects in target organs, and local THs may play a direct role in physiological functions. Although the presence of THs in human FF was verified in 1993 [15], the concentration of THs in FF has been analysed in only a small number of studies [16, 17]. One preliminary observational study found that fT4 in FF were higher in infertile patients than in the healthy population [18]. However, data from literature are not sufficiently clear to definitely state the relationship between serum and FF TH levels and the outcomes of assisted reproductive technology (ART), such as in vitro fertilisation (IVF).

Previous studies used only serum TSH as a biomarker to evaluate thyroid function. The aim of our study was to compare the relationship of serum and FF TH levels with cycle parameters and ART outcomes...

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Patients and sample collection
This prospective study involved a cohort of subfertile women who underwent one IVF or IVF-intracytoplasmic sperm injection (ICSI) cycle. For this study, two hundred and ninety-nine subfertile women were enrolled. A total of 165 FF samples were collected for the final analysis. TSH levels were determined at the first visit to our clinical center. Only patients with normal TSH and a baseline TSH levels were determined at the first visit to our clinical center. Only patients with normal TSH and a baseline TSH level <10 IU/L were included in the study. We excluded women with pre-existing thyroid disease and normal TSH levels as euthyroid.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.

Materials and methods
This study was approved by the Ethics Committee of the First People’s Hospital of Yunnan Province and was carried out according to good clinical practices. Informed consent was obtained from each patient.
T3 levels (1.97 ± 0.33 vs 2.10 ± 0.32 nmol/l, p ≤ 0.001) were found between serum and FF. Moreover, fT4 and fT3 followed the same trend, but the differences did not reach statistical significance.

**Relationship and difference between serum and follicular fluid thyroid autoantibodies**

Our results showed a significant correlation between serum and FF TPOAbs (r = 0.808, p ≤ 0.001) and TGAbs (r = 0.601, p ≤ 0.001).

TPOAb [15.27 (8.94, 19.9) vs 9.37 (5, 12.7) IU/ml, p ≤ 0.001] and TGAbs [17.6 (14.8, 20.5) vs 15.6 (13.7, 20.3), p = 0.021] were higher in serum than in FF.

No statistically significant differences in serum TSH (2.53 ± 1.03 vs 2.22 ± 1.15 mIU/ml, p = 0.762), T4 (116.2 ± 10.63 vs 118.81 ± 23.48 nmol/l, p = 0.941), T3 (1.93 ± 0.12 vs 1.98 ± 0.34 nmol/l, p = 0.461), fT4 (19.55 ± 2.7 vs 19.16 ± 3.11 pmol/l, p = 0.169) and fT3 levels (4.68 ± 0.32 vs 4.55 ± 0.73 pmol/l, p = 0.154) were found between patients with and without thyroid autoantibodies.

**Serum and follicular fluid parameters and ART characteristics and outcomes**

We observed slightly higher serum T4 levels [121.9 (104.8, 140.8) vs 114.1 (98.6, 130.6) nmol/l, p = 0.026], serum fT4 levels [19.0 (17.7, 21.8) vs 18.6 (17.0, 20.1) pmol/l, p = 0.026], serum T4/T3 ratios [62.5 (55.7, 66.2) vs 59.4 (53.4, 64.9), p = 0.029], FF fT4 levels [19.0 (17.5, 21.3) vs 18.1 (16.8, 19.9) pmol/l, p = 0.009] and FF T4/T3 ratios [52.6 (46.4, 57.3) vs 50.0 (43.7, 53.1), p = 0.004] in women with a successful pregnancy than in women with implantation failure in the respective treatment cycle. In terms of TSH, T3, T4, TPOAbs and TGAbs in serum and FF, there were no significant differences between the two groups (Table 1).

Spearman’s rank correlation analysis showed positive associations of both the FF T4/T3 ratio and serum TSH levels with the number of retrieved oocytes (total or MII) and the number of embryos (fertilized, cleavage, and good quality). These associations were slightly stronger for serum TSH than for FF T4/T3 (Table 2). On the other hand, the positive correlations observed between TSH and the number of good quality oocytes were stronger for serum than for FF (serum TSH r = 0.41, p ≤ 0.001; FF TSH r = 0.31, p ≤ 0.001).

No statistically significant correlation was found between the number of retrieved oocytes or fertilized oocytes and the levels of thyroid autoantibodies in serum or FF (data not shown).

Strong negative correlations of serum and FF fT4 levels with serum oestradiol (E2) were observed, but no such correlations were observed with FF E2 levels. The opposite correlation patterns were found between serum E2 levels and serum TSH levels.

BMI had a statistically significant impact on ART outcome (p ≤ 0.001). Different aetiologies of infertility (male, female, both male and female, and unknown cause) did not have a statistically significant impact on ART outcome (p = 0.395).

**Discussion**

The present study verified the presence of THs and thyroid autoantibodies in the FF of women undergoing ART and assessed the impact of these factors on embryonic development and ART outcomes. We demonstrated the presence of TSH, T4, T3, fT4, fT3 and thyroid autoantibodies in FF, and estimated their impact on fertilization and embryo development during ART. Our study highlighted that the majority of patients have FF TH levels within the normal range [15, 16]. We also observed a significant positive correlation between serum and FF TH levels, indicating that the majority of THs detected in FF seem to be derived from peripheral blood and enter follicles through theca interna cells. Moreover, we detected significantly higher concentrations of T3 in FF than in serum, whereas T4 concentrations were higher in serum than in FF, which is in line with the findings of previous studies [15, 17]. Our work also showed that the T4/T3 ratio was much lower in FF than in blood, which supports the presence of an ovarian 5′-monodeiodinase system in FF capable of generating T3 (ovary-generated T3) by outer ring deiodination of T4 [17]. We also detected thyroid autoantibodies in FF, but the levels were much lower than in serum. The results suggest that the blood-follicle barrier is a permselective barrier for thyroid autoantibodies.

The pivotal role of THs in several aspects of female reproduction have been well documented by several investigators. THs may impact folliculogenesis [19–21], ovarian steroidogenesis [22], and endometrial receptivity [23]. There is evidence that thyroid function is associated with pregnancy outcome, particularly in IVF. Despite treatment, women with hypothyroidism may have lower chances of pregnancy success after IVF [24]. SCH may also impact reproduction, and treatment of women with SCH has shown to improve IVF outcomes [25, 26], including increasing the rates of implantation, clinical pregnancy, and delivery.

Because of the strong associations of SCH with subfertility, the definition of euthyroidism in subfertile women is currently a topic of debate. TSH is considered the most sensitive test for thyroid function, so currently, studies investigating the association between SCH and infertility are based on serum TSH levels. In the present study, we showed no difference in TSH levels in euthyroid women undergoing ART among different IVF outcome groups. Our results are in line with those recently reported by Karmon AE et al. [6–8]. In the group of euthyroid women undergoing infertility treatment with...
ART, the authors observed no significant differences in clinical pregnancy or delivery rates among euthyroid infertile women with different preconceptional TSH levels after IUI.

However, evidence is lacking to support the use of T4 or fT4 to categorize euthyroid infertile women undergoing IVF and to predict pregnancy outcomes. It is unknown whether distinctions can be made among TH values within the normal range of TSH and the chances of certain fertility outcomes. In the current study, the major differences between women achieving pregnancy and those who experienced implantation failure were in serum T4, fT4 levels and the T4/T3 ratio. This discrepancy among TSH, T4 and fT4 levels might be explained by the physiology: COS-induced hyperestrogenism directly reduces serum fT4 levels by stimulating thyroid binding globulin (TBG) production, whereas the increase in serum TSH levels is achieved by a negative feedback

| Variables                      | Successful Pregnancy (N = 72) | Implantation Failure (N = 93) | P value |
|-------------------------------|------------------------------|-------------------------------|---------|
| Age (yrs)                     | 31 (28,34)                   | 34 (28,36)                    | NS      |
| BMI (kg/m2)                   | 22.5 (20.6,25.2)             | 20.8 (18.9,22.6)              | ≤0.001  |
| Basal FSH                     | 3.63 (1.95,6.01)             | 4.22 (1.79,7.11)              | NS      |
| AMH (ng/ml)                   | 3.56 (1.78,3.91)             | 3.46 (2.25,4.13)              | NS      |
| Oocytes (total)               | 13.5 (8.8,16.8)              | 10 (7,14)                     | 0.007   |
| Oocyte (MII)                  | 10.5 (5.5,15)                | 8 (6,10)                      | 0.002   |
| Fertilization rate,%          | 65.9%                        | 56.6%                         | ≤0.001  |
| Etiology of infertility(%)    | 75%                          | 77.4%                         | 0.395   |
| Female infertility            | 16.7%                        | 9.7%                          |         |
| Both male and female infertility| 8.3%                        | 12.9%                         |         |
| Infertility of unknown cause  | 98%                          | 99.5%                         | NS      |
| Serum (day HCG) hormone levels|                             |                               |         |
| TSH (mIU/l)                   | 1.86 (1.27,3.08)             | 1.95 (1.54,2.95)              | NS      |
| T4(nmol/l)                    | 121.9 (104.8,140.8)          | 114.1 (98.6,130.6)            | 0.026   |
| T3(nmol/l)                    | 1.98 (1.74,2.22)             | 1.98 (1.75,2.13)              | NS      |
| fT4(pmol/l)                   | 19.0 (17.2,21.8)             | 18.6 (17.0,20.1)              | 0.026   |
| fT3(pmol/l)                   | 4.75 (4.25,4.93)             | 4.5 (4.08,4.8)                | NS      |
| TPO Ab (IU/ml)                | 15.1 (9.17,23.22)            | 15.5 (8.94,17.52)             | NS      |
| TG Ab (IU/ml)                 | 16.6 (13.86,22.2)            | 14.4 (13.3,19.9)              | NS      |
| T4/T3                         | 62.5 (55.7,66.2)             | 59.4 (53.4,64.9)              | 0.029   |
| Follicular fluid hormone levels|                             |                               |         |
| TSH (mIU/l)                   | 2.12 (1.41,3.57)             | 2.41 (2.03,3.23)              | NS      |
| T4(nmol/l)                    | 112.3 (93.7,124.5)           | 102.6 (88.6,116.8)            | NS      |
| T3(nmol/l)                    | 2.07 (1.88,2.22)             | 1.98 (1.75,2.13)              | NS      |
| fT4(pmol/l)                   | 19.0 (17.5,21.3)             | 18.1 (16.8,19.9)              | 0.009   |
| fT3(pmol/l)                   | 4.67 (4.33,5.0)              | 4.19 (4.20,4.8)               | NS      |
| TPO Ab (IU/ml)                | 8.4 (5.0,13.9)               | 10.1 (5.0,12.7)               | NS      |
| TG Ab (IU/ml)                 | 17.5 (13.98,24.38)           | 17.6 (14.9,20.3)              | NS      |
| T4/T3                         | 52.6 (46.4,57.3)             | 50.0 (43.7,53.1)              | 0.004   |

Note: Values are Mean± SD, median and interquartile range, or n (%) as indicated
NS nonsignificant, which means P ≥ 0.05
FF follicular fluid, BMI body mass index, AMH anti-Mullerian hormone
| Parameter                  | TSH Serum | FF | T4 Serum | FF | T4/T3 Serum | FF | FT4 Serum | FF |
|---------------------------|-----------|----|----------|----|-------------|----|-----------|----|
| Oocytes (total)           | 0.0165 \(r = 0.186\) | 0.478 | 0.0474 \(r = 0.155\) | 0.313 | 0.043 \(r = 0.159\) | 0.08 | 0.356 |
| Oocyte (MII)              | 0.008 \(r = 0.205\) | 0.103 | 0.005 \(r = 0.216\) | 0.713 | 0.03 \(r = 0.166\) | 0.191 | 0.874 |
| Fertilized embryos       | 0.019 \(r = 0.182\) | 0.251 | 0.003 \(r = 0.228\) | 0.199 | 0.001 \(r = 0.253\) | 0.478 | 0.624 |
| Cleavage embryos         | 0.001 \(r = 0.271\) | 0.0726 | 0.004 \(r = 0.226\) | 0.08 | 0.005 \(r = 0.271\) | 0.42 | 0.68 |
| Good quality embryos     | 0.001 \(r = 0.41\) | 0.001 \(r = 0.31\) | 0.633 | 0.2 | 0.02 \(r = 0.18\) | 0.003 \(r = 0.227\) | 0.596 | 0.908 |
| E2 (HCG day)             | 0.001 \(r = 0.324\) | 0.01 \(r = 0.203\) | 0.003 \(r = -0.28\) | 0.01 \(r = -0.20\) | 0.004 \(r = -0.226\) | 0.08 | 0.001 \(r = -0.428\) | 0.001 \(r = -0.428\) |
| E2 (FF)                  | 0.552     | 0.575 | 0.789     | 0.302 | 0.916       | 0.89 | 0.273     | 0.302 |

Note: FF follicular fluid, E2 oestradiol, HCG human chorionic gonadotropin
loop [27, 28]. Taken together, these data suggest that when there is a rapid increase in TBG leading to high variability in fT4 levels, the changes in TSH lags. Our study results show that the determination of fT4 levels and the T4/T3 ratio in serum on the day of OPU, together with TSH, maybe have greater prognostic value than TSH alone.

A growing body of literature indicates that the hormon-al follicular milieu, which includes anti-Mullerian hormone and inhibin B, is correlated with reproductive outcome after IVF [29]. However, few studies have examined the possible association between FF THs and IVF outcomes. Our results are the first to show a link among the FF T4/T3 ratio, embryonic developmental competence and successful pregnancy. Embryo quality is an important predictor of ART success. As expected, the successful pregnancy group had a significantly higher mean number of blastomeres, MII oocytes and retrieved oocytes than the implantation failure group. Significant correlations were found between the numbers of retrieved oocytes and fertilized oocytes and serum TSH levels and the FF T4/T3 ratio. Kamron’s study advocates that thyroid function in subfertile women could indicate an insufficient capacity for basic reproductive functions such as oocyte quality, ovulation, fertilization and implantation [30]. Free TH supplementation (50 ng/ml of T3 and T4) led to significant increases in blastocyst formation and hatching rates in bovine embryos [31], and in the expansion rate of the blastocoel cavity of cryopreserved bovine embryos. Although an exact mechanism cannot be assumed, it is noteworthy that thyroid dysfunction may impact IVF outcomes, possibly at the level of oocyte quality.

No statistically significant difference was found between groups in the levels of thyroid autoantibodies in serum and FF. There was no statistically significant correlation between the number of retrieved oocytes or fertilized oocytes and the levels of thyroid autoantibodies in serum and FF. These findings support the theory that thyroid autoantibodies in FF do not affect oocyte number, oocyte maturation, or quality or preimplantation embryos during ART [32, 33]. However, other studies which only focus on serum TAI have found a lower fertilization rate in the thyroid autoimmunity (TAI)-positive group in the TAI-negative group (63 vs 72% [34] and 64.3 vs 74.6% [35]). One of the limitations of our study and other study included FF TAI to analysis is the relatively small number of TAI-positive patients. Our study included 165 (15 TAI positive) patients, while Medenica’s study included 52 (26 TAI positive) patients [32]. In addition, a previous study showed that thyroid antibodies cancer cross-react with zona pellucida and granulosa cells due to molecular mimicry [36].

Our results revealed significant negative correlations between serum E2 and fT4 in serum and FF. Not surprisingly, we also found a significant positive correlation between serum E2 and serum TSH, which could be explained by the COS-specific changes in oestrogen levels. A previous study showed that COS could lead to hyperestrogenism, through a rise in TBG, subsequently leading to a decrease in fT4 [27]. Our results support the theory that the adaptation of maternal TH metabolism to hyperestrogenism during pregnancy may be important for embryo survival [30, 31]. Similarly, COS-specific changes might put stress on hypothalamus-pituitary-thyroid axis in a very short time and manifest as gestational thyroid disease, which subsequently creates a suboptimal environment during the early phase of implantation, which may increase the risk for IVF failure.

The use of a population of infertile women undergoing ART has some limitations. First, our outcomes were limited to cycle parameters and clinical pregnancy. Therefore, no conclusions can be drawn on any other obstetric or fetal end points. Second, whether these findings are generalizable to women without known fertility problems is still under debate. Additionally, a strong association between TH levels and pregnancy rate could not be found.

In conclusion, thyroid autoantibodies and most THs present in FF are not generated in the FF, but rather enter from the blood. Thyroid autoantibodies do not directly impact oocytes and embryos during ART, but on the OPU day, the T4/T3 ratios in both serum and FF were significantly higher in the group of women who became pregnant than in those who did not conceive. Our results highlight the importance of the adaptation of TH metabolism during COS.

Moreover, one point of practical importance regarding our study results is the confirmation of a strong correlation between serum and FF TH levels, which suggests that the complicated determinations of FF TH levels may not be necessary because serum TH levels provide the same information. Further studies with more samples should be performed to confirm our findings and to elucidate the relationships among ovarian stimulation protocols, oocyte quality, clinical pregnancy rate and longitudinal changes of THs levels during COS.

Acknowledgements
The authors thank the staff of Reproductive Medicine Center and Endocrinology Laboratory of The First People’s Hospital of Yunnan P.R. China for sample collection.

Authors’ contributions
Patient selection: Y. C and LN; sample collection and processing: L. N and LZ; sample measurements: Y. D and H.D; data analysis and interpretation: Y. C and LN; study design: H. S and Z.W; manuscript drafting: Y. C and H.S. All authors read and approved the final manuscript.

Funding
The present study was supported by Natural Science Foundation of China (Grant NO.81760143), Foundation for High-level Talents of Yunnan, China (Grant NO.L-201624) and Science and Technology Program of Yunnan, China (Grant NO.U0120170150).
Availability of data and materials
The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.

Ethics approval and consent to participate
All experiments were performed in strict accordance with the Ethics Committee at The First People's Hospital of Yunnan P.R. China. Informed consent was obtained from all subjects. The Institutional Committee of the First People's Hospital of Yunnan P.R. China approved the experimental protocols (registration number: 2017YY138).

Consent for publication
All co-authors have seen and approved the final version of the paper and have agreed to its submission for publication. All patients signed informed written consent forms.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical School, Kunming University of Science and Technology, Kunming 650500, Yunnan Province, China. 2 Department of Endocrinology, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650500, Yunnan Province, China. 3 Reproductive Medicine Center, The Affiliated Hospital of Kunming University of Science and Technology, Kunming 650500, Yunnan Province, People's Republic of China.

Received: 11 April 2019 Accepted: 4 October 2019
Published online: 07 November 2019

References
1. Silva JF, Ocarino NM, Serakides R. Thyroid hormones and female reproduction. BioRepil 2018;59(9):507–521. PMID: 29767691
2. Poppe K, Velkeniers B. Female infertility and the thyroid. Best Pract Res Clin Endocrinol Metab 2004;18(2):153–165. PMID: 15157833
3. Rao M, Zeng Z, Zhao S, Tang L. Effect of levothyroxine supplementation on pregnancy outcomes in women with subclinical hypothyroidism and thyroid autoimmunity undergoing in vitro fertilization/intracytoplasmic sperm injection: an updated meta-analysis of randomized controlled trials. Reprod BioEndocrinol. 2018;16(1):92. PMID: 30249251
4. Zhao T, Chen BM, Zhao XM, Shan ZY. Meta-analysis of ART outcomes in women with different preconception TSH levels. Reprod BioEndocrinol. 2018;16(1):111. PMID: 30396353
5. Reh A, Grifo J, Danforth A. What is a normal thyroid-stimulating hormone (TSH) level? Effects of stricter TSH thresholds on pregnancy outcomes after in vitro fertilization. Fertil Steril. 2010;94(7):2920–2922. PMID: 20655528
6. Karmon AE, Batsis M, Chavarro JE, Souter I. Preconception thyroid-antimüllerian hormone levels. Hum Reprod 2017;32(6):1596–1605. PMID: 22451503
7. Reh A, Grifo J, Danforth A. What is a normal thyroid-stimulating hormone (TSH) level? Effects of stricter TSH thresholds on pregnancy outcomes after in vitro fertilization/intracytoplasmic sperm injection: an updated meta-analysis of randomized controlled trials. Reprod BioEndocrinol. 2018;16(1):92. PMID: 30249251
8. Zhao T, Chen BM, Zhao XM, Shan ZY. Meta-analysis of ART outcomes in women with different preconception TSH levels. Reprod BioEndocrinol. 2018;16(1):111. PMID: 30396353
9. Reh A, Grifo J, Danforth A. What is a normal thyroid-stimulating hormone (TSH) level? Effects of stricter TSH thresholds on pregnancy outcomes after in vitro fertilization. Fertil Steril. 2010;94(7):2920–2922. PMID: 20655528
10. Karmon AE, Batsis M, Chavarro JE, Souter I. Preconception thyroid-antimüllerian hormone levels. Hum Reprod 2017;32(6):1596–1605. PMID: 22451503
11. de los Santos MJ, García-Láez V, Beltrán-Torrejosa D, Horcajadas JA, Martínez-Conjerro JA, Esteban FJ, Pellicer A, Labarta E. Hormonal and molecular characterization of follicular fluid, cumulus cells and oocytes from pre-ovulatory follicles in stimulated and unstimulated cycles. Hum Reprod 2012;27(8):1596–1605. PMID: 22451503
12. Cavallo IK, Dela Cruz C, Oliveira ML, Del Puerto HL, Dias JA, Lobach VN, Casalechi M, Camargos MG, Reis AM, Santos RA, Reis FM. Angiotensin-(1-7) in human follicular fluid correlates with oocyte maturation. Hum Reprod 2017 Jun 132(6):1318–1324. PMID: 28402544
13. Schweizer U, Steegborn C. New insights into the structure and mechanism of iodothyroninedioledianines. J Mol Endocrinol. 2015;55(3):R37–R52. PMID: 25698881
14. Williams GR, Bassett JH. Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol. 2011;209(3):261–272. PMID: 21292729
15. Wakim AN, Polizotto SL, Buffo MJ, Marerro MA, Burholt DR. Thyroid hormones in human follicular fluid and thyroid hormone receptors in human granulocells. Fertil Steril. 1993;59(6):1187–1190. PMID: 8495763
16. De Silva M. Detection and measurement of thyroid stimulating hormone in human follicular fluid. J Reprod Med 1994;39(9):679–680. PMID: 7807478
17. Sebodzinski AB. Ovarian iodide uptake and triiodothyronine generation in follicular fluid. The enigma of the thyroid ovary interaction. Domest Anim Endocrinol. 2005;29(1):97–103. Epub 2005 Apr 7.
18. Cediková M, Babuška V, Rajdl D, Zech NH, Kalivá Králíková M. Comparison of prolactin, free T3 and free T4 levels in the follicular fluid of infertile women and healthy fertile oocyte donors. Ceska Gynekol. 2012;77(5):471–476. PMID: 23116354.
19. Verga Falzaccapa C, Timperi E, Bucci B, Amendola D, Piergrossi P, D'Amico D, Santaguida MG, Centenni M, Mistsi S. T3 (3) preserves ovarian granulosa cells from chemotherapy-induced apoptosis. J Endocrinol. 2012 Nov 21;212(3):281–289. PMID: 22911894.
20. Zhang C, Guo L, Zhu B, Feng Y, Yu S, An N, Wang X. Effects of 3, 5, 3'-triiodothyronine (t3) and follicle stimulating hormone on apoptosis and proliferation of rat ovarian granulosa cells. Chin J Physiol 2013;56(3):298–305. PMID: 24302715
21. Fedail JS, Zheng K, Wei Q, Kong L, Shi F. Roles of thyroid hormones in follicular development in the ovary of neonatal and immature rats. Endocrine. 2014;48(3):594–604. PMID: 24254997
22. Cecconi S, Rucchi N, Scaldaferrifici ML, Masciulli MP, Rossi G, Moretti C, D‘Armiento M, Ullisse S. Thyroid hormone effects on mouse oocyte maturation and granulosa cell aromatase activity. Endocrinology. 1999 Apr 140(4):1783–1788. PMID: 10098516
23. Aghajanova L, Stavreus-Evers A, Lindeberg M, Landgren BM, Sparre LS, Hovatta O. Thyroid-stimulating hormone receptor and thyroid hormone receptors are involved in human endometrial physiology. Fertil Steril. 2011 Jan;95(1):230–237, 237.e1–2. PMID: 20691434
24. Poppe K, Velkeniers B, Gilmore D. Thyroid disease and female reproduction. Clin Endocrinol 2007;66(3):309–321. PMID: 17302862
25. Abdel Rahman AH, Aly Abbassy H, Abbassy AA. Improved in vitro fertilization outcomes after treatment of subclinical hypothyroidism in infertile women (J). A EndoPract. 2010;16(5):792–797. PMID: 20350020
26. Kim CH, Ahn JW, Kang SP, et al. Effect of levothyroxine treatment on in vitro fertilization and pregnancy outcome in infertile women with subclinical hypothyroidism undergoing in vitro fertilization/ intracytoplasmic sperm injection (J). Fertil Steril. 2011;95(5):1650–1654. PMID: 21193190
27. Muller AF, Verhoeff A, Mantel MJ, De Jong FH, Berghout A. Decrease of free thyroxine levels after controlled ovarian hyperstimulation. J Clin EndocrinolMetab 2000;85(2):545–548. PMID: 10690853
28. Korevaar TIM, Medici M, Visser TJ, Peeters RP. Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol. 2017;13(10):610–22. PMID: 28776582
29. Wunder DM, Guburdhenche J, Birnhäuser MH, Bensinger NA. Anti-Müllerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril. 2008;90(6):2030–2035. Epub 2008 Feb 21.
30. Karmon AE, Cardozo BR, Souter I, Gold J, Petrozza JC, Sayer AK. Donor TSH level is associated with clinical pregnancy among oocyte donation cycles. J Assist ReprodGenet 2016;33(4):489–494. PMID: 26847132
31. Ashkar FA, Semple E, Schmidt CH, St John E, Bartlewski PM, King WA. Thyroid hormone supplementation improves bovine embryo development in vitro. Hum Reprod 2010;25(2):334–344. PMID: 19920067
32. Medenica S, Galajecic E, Arsic B, Medjo B, Bojovicovic D, Abazovic D, Vukovic R, Zarkovic M. Follicular fluid thyroid autoantibodies, thyrotropin, free thyroxine levels and assisted reproductive technology outcome. PLoS One 2018;13(10):e0206652. PMID: 30572494
33. Monteleone P, Parrini D, Faviana P, Carletti E, Casarosa E, Uccelli A, Cela V, Genazzani AR, Artini PG. Female infertility related to thyroid autoimmunity: the ovarian follicle hypothesis. Am J Reprod Immunol. 2011;66(2):108–114. doi: https://doi.org/10.1111/j.1600-0897.2010.00961.x. Epub 2011 Jan 18. PMID: 21241400.

34. Poppe K, Velkeniers B, Glinoer D. The role of thyroid autoimmunity in fertility and pregnancy. Nat Clin Pract Endocrinol Metab. 2008;4(7):394–405. 18506157. https://doi.org/10.1038/ncpendmet0846.

35. Zhong YP, Ying Y, Wu HT, Zhou CQ, Xu YW, Wang Q, Li J, Shen XT, Li J. Relationship between antithyroid antibody and pregnancy outcome following in vitro fertilization and embryo transfer. Int J Med Sci 2012;9(2):121–125. doi: https://doi.org/10.7150/ijms.3467. Epub 2012 Jan 5. PMID: 22253557.

36. Kelkar RL, Meherji PK, Kadam SS, Gupta SK, Nandedkar TD. Circulating auto-antibodies against the zonapellucida and thyroid microsomal antigen in women with premature ovarian failure. J Reprod Immunol 2005;66(1):53–67. PMID: 15949562.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.